Oss, September, 14, 2020 – The 18th Discovery on Target (DOT) conference on innovative drug discovery will be in digital format this year. Dr. Guido Zaman, Managing Director and Head of Biology of NTRC, will present at the Kinase Inhibitor Discovery Symposium, held on Thursday and Friday, September 17th and 18th.
Recently, the first tumor-agnostic kinase inhibitors, targeting NTRK gene fusions in solid tumors, and several new mechanisms have been addressed, including selective targeting of FGFR and RET. The presentation concerns clustering analysis of recently approved kinase inhibitors (2018 – 2020) on the basis of profiling in a broad cancer cell line panel (Oncolines™). The work proceeds on the work of two earlier published studies [1,2] on clinically approved kinase inhibitors. So far, more than hundred kinase inhibitors have been profiled in the Oncolines™ cancer cell line panel. Approximately half of them are clinically approved drugs (indicated in red in the clustering wheel). The selectivity of these compounds on a panel of 280 biochemical kinase enzyme assays have also been determined (at Carna Biosciences, Inc.). In the presentation at the DOT virtual conference, Guido Zaman will relate the biochemical and the cellular selectivity of recently approved kinase inhibitors, including inhibitors of BRAF, FLT3 and FGFR. All case studies are new and have not been presented or published before.
Discovery on Target Kinase Inhibitor Symposium. Title of presentation: “Biochemical and cellular selectivity of recently approved kinase inhibitors” Time: 2.05 p.m. (EDT) / 8.05 p.m. (CET).
 Uitdehaag JCM, de Roos JADM, van Doornmalen AM, Prinsen MBW, de Man J, Tanizawa Y, et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE 2014;9:e92146.
 Uitdehaag JCM, Kooijman JJ, de Roos JADM, Prinsen MBW, Dylus J, Willemsen-Seegers N, et al. Combined cellular and biochemical profiing to identify drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Mol. Cancer Ther. 2019;18:470-81.